$ACOG

Opaleye Management Inc. purchased $1.6M of ACOG (indirect holdings)

Opaleye Management Inc. purchased 200,086 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $7.82 ($7.80–$7.83, $1.57M total) across 3 trades over 2026-07-22 to 2026-07-23.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Jul 24, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

A new Form 4 details an open-market purchase by a 10% owner via indirect holdings, which can slightly influence short-term sentiment but is unlikely to drive fundamentals by itself.

02

Market read

Traders may monitor ACOG for follow-on insider activity, but the disclosure alone is not a catalyst like earnings, guidance, or a deal.

03

What to watch

The article does not state the insider’s prior cost basis, whether other insiders also bought/sold, or any concurrent company-specific catalysts, so the trading signal may be weak.

Relevance 7/10Novelty 6/10Timing: filed today on SEC EDGAR, covering trades from 2026-07-22 to 2026-07-23

Background

The article is an SEC Form 4 insider transaction disclosure for Alpha Cognition Inc. (ACOG).

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc., a 10% owner, filed a Form 4 showing an open-market purchase of 200,086 shares of ACOG for about $1.57M.

Expected impact

Likely limited near-term impact; may modestly support sentiment if traders treat the buy as bullish.

Evidence & confidence

Form 4 provides fresh transaction details (size, dates, price range) but insider buying is not the same as fundamental guidance, and the indirect nature reduces interpretability.

Market effects

No sector-level implications; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Indirect ownership and absence of a 10b5-1 plan do not necessarily imply conviction; it could reflect routine rebalancing or liquidity needs.

Key entities

  • Alpha Cognition Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Opaleye Management Inc.

    Reporter and 10% owner making an indirect open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.